Showing 591-600 of 8647 results for "".
Have a Young Patient With Computer Vision Syndrome?
https://modernod.com/articles/significant-findings/have-a-young-patient-with-computer-vision-syndrome/37829/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatGot a Corneal Wound? Breast Milk Could Help
https://modernod.com/articles/significant-findings/got-a-corneal-wound-breast-milk-could-help/37826/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatInterested in Stroke Risk?
https://modernod.com/articles/significant-findings/interested-in-stroke-risk/37825/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatMultifocals for Myopia?
https://modernod.com/articles/significant-findings/multifocals-for-myopia/37824/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatA Lesson From Carrie Underwood
https://modernod.com/articles/significant-findings/a-lesson-from-carrie-underwood/37822/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatLet’s Talk Optometry Standards and Schools
https://modernod.com/articles/significant-findings/lets-talk-optometry-standards-and-schools/37821/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatThe Doctor Is in, Case Closed
https://modernod.com/articles/significant-findings/the-doctor-is-in-case-closed/37820/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatOSD’s Greatest Hits: 2024 Edition
https://modernod.com/podcasts/to-the-point/osds-greatest-hits-2024-edition/36942/In this month’s episode of To the Point, Jackie Garlich, OD, FAAO, and Cecelia Koetting, OD, FAAO, Dipl ABO, talk about the most exciting, important, and novel ocular surface disease (OSD) news to come out of the past year, including FDA approvals, product launches, new clinical data, and more. They2024 Year in Review — Part 2
https://modernod.com/podcasts/eyewire-news-the-podcast/2024-year-in-review-part-2/37065/In today’s episode, we review the top stories from the second half of 2024. The last six months saw the launch of first-of-its-kind IOLS; the clinical advancement of gene therapies for rare diseases; the FDA approval of a device to treat patients with dry AMD; and introduction of novel OCTA technolo2024 Year in Review — Part 1
https://modernod.com/podcasts/eyewire-news-the-podcast/2024-year-in-review-part-1/37064/In today’s broadcast, we look back at the top stories from the first half of 2024. There were several advancements made during the first six months., including the approval of an excimer laser platform; the global adoption of sustained-released anti-VEGF treatments for retinal diseases; the rollout